Medytox is making its move into the Latin American market with its hyaluronic acid (HA) filler, 'Atier.'
On June 24, Medytox announced that it has received product approval for three types of 'Atier' from the Dominican Republic's Directorate General of Medicines, Food and Health Products (DIGEMAPS). This approval marks Atier's first entry into the Latin American market, following its introduction in Asia, including Thailand and Indonesia.
The Dominican Republic is experiencing rapid growth in its beauty and aesthetic market due to economic expansion and rising income levels. The popularity of Korean content has also increased the demand for Korean cosmetics and medical aesthetic products, making it a key target for K-aesthetic companies.
With this approval, Medytox has established a diverse filler lineup alongside its existing product, 'Nuramys,' which has been sold locally since 2017, laying a solid market foundation. The company stated, "We plan to actively leverage our existing sales and marketing capabilities to ensure the successful market entry of 'Atier Classic, Intensive, and Volume.'"
Medytox also anticipates synergies with its affiliate Newmecco's botulinum toxin product, 'Nulux,' which entered the Dominican Republic last year. The company aims to expand its local market share through a portfolio strategy that combines fillers and toxins.
A Medytox representative commented, "The entry into Latin America will further accelerate the global expansion of Atier. We aim to continuously expand into new countries and establish ourselves as a global filler brand."
Atier is a hyaluronic acid filler developed in-house by Medytox, characterized by an optimized balance of elasticity and viscosity. The manufacturing process does not use animal-derived media or enzymes, enhancing safety, and it utilizes ingredients registered with the U.S. Food and Drug Administration (FDA) and certified by the European Directorate for the Quality of Medicines (EDQM). The company is accelerating its overseas market expansion, starting with approvals in Indonesia and Thailand in 2024.
The global medical aesthetic market is rapidly growing. According to market research firm Research Nester, the global skin filler market is projected to grow from $5.92 billion last year to $14.67 billion by 2035, with an estimated annual growth rate of about 9.5%.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.